Financial Performance - Operating revenue for the period reached ¥1,424,735,670.05, reflecting a growth of 19.06% year-on-year[8] - Net profit attributable to shareholders was ¥151,250,347.12, up by 15.59% compared to the same period last year[8] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥150,255,378.97, an increase of 25.44% year-on-year[8] - Basic earnings per share were ¥0.16, representing a growth of 14.29% compared to the same period last year[8] - The weighted average return on equity was 4.92%, a slight increase of 0.16% compared to the previous year[8] - The company expects a net profit attributable to shareholders to decline by 30% to 0%, estimating a range of RMB 28,500.49 to RMB 40,714.98 for 2018[21] Assets and Liabilities - Total assets increased to ¥6,784,314,014.98, a rise of 15.52% compared to the end of the previous year[8] - Accounts receivable increased by 226.93% to RMB 647,271,115.58 due to year-end settlement of government procurement in the pharmaceutical business[18] - Other receivables surged by 722.78% to RMB 226,179,340.24, primarily due to loans made to Tachen Huitong and others[18] - Short-term borrowings rose by 59.74% to RMB 1,329,000,000.00, attributed to increased loans from expanded business operations[18] - Financial expenses increased by 107.85% to RMB 37,238,086.01, driven by higher loan costs due to business expansion[18] - The company reported a 49.03% decrease in advance receipts to RMB 129,688,984.91, as the plant protein business completed its sales for the season[18] Shareholder Information - The total number of shareholders at the end of the reporting period was 963,402,312[12] - The largest shareholder, Xinjiang Production and Construction Corps State-owned Assets Management Co., held 29.47% of the shares[12] Corporate Actions - The company plans to repurchase shares using its own funds, with a budget between RMB 100 million and RMB 200 million, at a price not exceeding RMB 7 per share[17] Compliance and Commitments - The company reported no significant changes in its non-recurring gains and losses during the reporting period[10] - The company has no overdue commitments from controlling shareholders or related parties during the reporting period[20] - There were no instances of non-compliance with external guarantees during the reporting period[23] Cash Flow - Cash flow from operating activities showed a significant decline, with a net amount of ¥41,993,013.36, down 84.04% year-on-year[8] Investment Performance - Investment income improved by 187.43% to ¥927,627.85, reflecting better operational performance of investment projects[18]

Financial Performance - The company's operating revenue for the first half of 2018 was ¥2,286,098,674.60, representing a 0.73% increase compared to ¥2,269,473,254.95 in the same period last year[21]. - The net profit attributable to shareholders decreased by 43.05% to ¥108,064,818.61 from ¥189,752,358.05 year-on-year[21]. - Basic and diluted earnings per share fell by 45.00% to ¥0.11 from ¥0.20 in the same period last year[21]. - The company reported a net profit of CNY 110,762,315.11 for the first half of 2018, reflecting a decrease in profitability compared to the previous year[162]. - The net profit for the first half of 2018 was CNY 74,147,612.20, down from CNY 98,562,712.79 in the same period last year, representing a decline of approximately 24.7%[167]. - The total comprehensive income for the first half of 2018 was CNY 74,147,612.20[184]. Cash Flow and Liquidity - The net cash flow from operating activities dropped significantly by 82.53%, amounting to ¥37,256,860.74 compared to ¥213,309,644.91 in the previous year[21]. - The company's cash and cash equivalents at the end of the reporting period amounted to CNY 1,823,887,401, representing an increase of 6.93% compared to the previous year[48]. - The net cash flow from operating activities was -113,068,920.12 yuan, compared to -38,952,360.23 yuan in the previous period, indicating a decline in operational performance[174]. - The cash flow from tax refunds received was 1,878,427.35 yuan, contributing to the overall cash inflow from operating activities[173]. - The company reported a cash flow net increase of -10,992,058.04 yuan, contrasting with a positive increase of 162,903,162.64 yuan in the previous period[175]. Assets and Liabilities - The total assets of the company increased by 5.46% to ¥6,193,423,964.13 from ¥5,872,850,839.57 at the end of the previous year[21]. - Total liabilities increased to CNY 2,434,026,270.57 from CNY 2,074,244,003.05, reflecting a growth in financial obligations[161]. - The company's total equity was CNY 3,079,582,250.99, up from CNY 3,055,177,541.77 at the beginning of the year[157]. - The company's current ratio decreased by 39.89% to 162.92% compared to the previous year, attributed to an increase in accounts receivable due to unsettled government procurement[142]. Business Operations - The feed business sales revenue increased by 4.73% to CNY 1,156,445,911.44, while the pharmaceutical business sales revenue decreased by 4.77% to CNY 253,285,548.55[35]. - The revenue from pig farming increased by 23.38% year-on-year, totaling CNY 125,864,339.55, but the gross margin decreased by 36.18%[45][46]. - The company aims to become a leading health breeding service provider and safe food supplier in China, focusing on a complete industry chain from breeding to sales[29]. - The company plans to gradually expand the "company + farmer" breeding model as its pig farming scale increases[36]. Investment and Development - Research and development investment increased by 48.37% to CNY 28,676,973.68, reflecting the company's commitment to enhancing innovation capabilities[40]. - The company plans to enhance its animal vaccine and feed business to improve market competitiveness and risk resistance[79]. - The company plans to enhance its market expansion strategies and invest in new product development to drive future growth[182]. Risks and Challenges - The company faces risks related to livestock disease outbreaks, raw material price fluctuations, and food safety issues that could impact its performance[5][6][8]. - The company faces risks from fluctuations in raw material prices, particularly corn and soybean meal, which could negatively impact its feed business[80]. - The cyclical fluctuations in livestock product prices have adversely affected the company's pig farming and feed business[81]. Shareholder and Governance - The company plans not to distribute cash dividends or issue bonus shares[9]. - The company has committed to distributing cash dividends of no less than 10% of the distributable profits achieved each year for the next three years[88]. - The company has not sold any significant assets during the reporting period[73]. - The company has not engaged in any asset or equity acquisitions or sales during the reporting period[95]. Compliance and Regulations - The financial report for the first half of 2018 has not been audited[89]. - The company has not faced any penalties or corrective actions during the reporting period[92]. - The company has committed to maintaining its independence in operations and management as per relevant laws and regulations[88].

2018 年第一季度报告正文 1 证券代码：002100 证券简称：天康生物 债券代码：128030 债券简称：天康转债 天康生物股份有限公司 2018 年第一季度报告正文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 天康生物股份有限公司 2018 年第一季度报告正文 公告编号：2018-035 天康生物股份有限公司 公司负责人杨焰、主管会计工作负责人耿立新及会计机构负责人(会计主管 人员)杨俊声明：保证季度报告中财务报表的真实、准确、完整。 2 天康生物股份有限公司 2018 年第一季度报告正文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | 营业收入（元） | 996,366,411.62 | 1,039,393,448.53 | -4.14% | | 归属 ...

Financial Performance - The company's operating revenue for 2017 was ¥4,630,025,738.72, representing a 4.18% increase from ¥4,444,138,122.88 in 2016[26]. - The net profit attributable to shareholders for 2017 was ¥407,149,786.08, up 3.72% from ¥392,541,388.03 in 2016[26]. - The net cash flow from operating activities increased by 105.45% to ¥649,327,329.99 in 2017 from ¥316,051,716.97 in 2016[26]. - The total assets at the end of 2017 were ¥5,872,850,839.57, a 30.77% increase from ¥4,490,817,872.34 at the end of 2016[27]. - The company's basic earnings per share for 2017 was ¥0.42, a 2.44% increase from ¥0.41 in 2016[26]. - The weighted average return on equity for 2017 was 14.66%, down from 15.82% in 2016[27]. - The company achieved a net profit of 441,280,988.82 yuan in 2017, exceeding the average net profit of the previous three years by 149,953,113.89 yuan[147]. Revenue Breakdown - The company's feed business sales revenue was 220,011.78 million yuan, a decrease of 0.91%, accounting for 47.52% of total operating revenue[47]. - The company sold 120,873.14 million doses (milliliters) of animal vaccines, a decrease of 4.57% year-on-year[48]. - The company's pharmaceutical business revenue was 67,617.54 million yuan, a decline of 10.05%, accounting for 14.60% of total operating revenue[48]. - The company's plant protein and oil processing business revenue increased by 34.58% year-on-year, totaling 84,350.84 million yuan[49]. - The company reported a 63.93% increase in revenue from live pigs, totaling approximately ¥198.63 million, compared to ¥121.17 million in 2016[56]. Investment and R&D - The company plans to invest no less than 10% of its revenue annually in R&D, targeting 2-3 new product launches each year with an expected annual growth rate of 20-30% for its veterinary medicine business[6]. - The company has recruited over 30 professionals for its R&D team to enhance its pharmaceutical technology development capabilities[5]. - R&D investment amounted to approximately ¥68.59 million in 2017, a decrease of 11.53% from ¥77.53 million in 2016, with R&D expenditure accounting for 1.48% of operating revenue[78]. - The company is developing a dual-inactivated vaccine for Porcine Circovirus Type 2 and Mycoplasma Pneumonia, which has shown high antigen expression and safety[67]. - The company is focusing on expanding its vaccine portfolio to address complex epidemic situations in border regions, particularly for small ruminant diseases[76]. Risk Management - The company acknowledges risks related to livestock disease outbreaks, raw material price fluctuations, and food safety, which could impact its financial performance[10][11][14]. - The company is addressing risks from livestock diseases by strengthening disease prevention measures and leveraging its vaccine and feed business for better market competitiveness[119]. - The company is mitigating risks from raw material price fluctuations by establishing storage companies in major production areas and diversifying raw material supply channels[120]. - The company is implementing strict management practices to ensure food safety and has adopted the HACCP management system to meet international standards[124]. Dividend and Profit Distribution - TianKang Bio's profit distribution plan includes a cash dividend of 1.00 RMB per 10 shares (before tax) for all shareholders[14]. - In 2017, the company distributed a cash dividend of 1.00 CNY per 10 shares, totaling 96,338,460.80 CNY, which represents 23.66% of the net profit attributable to shareholders[128]. - The company has committed to distributing cash dividends annually, with a minimum of 10% of the distributable profit for the year[136]. - The cash dividend payout ratio for 2015 was 47.03%, for 2016 was 24.54%, and for 2017 was 23.66%[130]. Corporate Governance and Compliance - The company has established commitments to ensure that related party transactions do not harm the legitimate rights and interests of its shareholders[133]. - The company has outlined measures to ensure compliance with legal obligations and to protect shareholder interests during the restructuring process[133]. - The company has established a complete governance structure and internal control system to ensure compliance with laws and regulations[168]. - The company has not engaged in any major related party transactions during the reporting period[149]. Future Plans and Growth Strategy - TianKang Bio aims to achieve over 10 billion RMB in revenue and over 1 billion RMB in profit by the end of the 13th Five-Year Plan[5]. - The company aims for a feed production and sales volume of 1.02 million tons, animal vaccine production of 1.6 billion doses (milliliters), and a pig output of 700,000 heads in 2018, with a revenue target of 5.128 billion yuan and a net profit of 365 million yuan after deducting non-recurring gains and losses[114]. - The company plans to gradually expand the "company + farmer" breeding model as its pig farming scale increases[50]. - The company is focusing on expanding its international business, particularly in the sales of E2 vaccines and foot-and-mouth disease vaccines[117].

Financial Performance - Net profit attributable to shareholders increased by 3.08% to CNY 130,849,143.58 for the current period[8] - Operating revenue rose by 9.51% to CNY 1,196,626,639.72 for the current period[8] - Basic earnings per share increased by 7.69% to CNY 0.14[8] - The net profit attributable to shareholders after deducting non-recurring gains and losses decreased by 3.83% to CNY 119,782,689.93[8] - The company reported a gross profit margin of approximately 11.6% for the quarter, down from 12.8% in the previous year[41] - Net profit attributable to shareholders was CNY 130,849,143.58, a slight increase from CNY 126,938,759.87, representing a growth of 2.4%[43] - The total comprehensive income for the quarter was CNY 130,314,647.82, compared to CNY 125,577,271.32 in the previous year, showing an increase of 3.0%[43] - The total profit for the quarter was CNY 330,058,787.57, down from CNY 351,231,514.25 in the previous year[48] Assets and Liabilities - Total assets increased by 4.99% to CNY 4,715,024,529.94 compared to the end of the previous year[8] - The total liabilities of the company were CNY 1,791,394,342.25, slightly up from CNY 1,786,571,256.12, showing a marginal increase of about 0.3%[36] - Total liabilities increased to CNY 1,324,310,579.64 from CNY 988,800,097.25, marking a significant rise of 33.9%[42] - The equity attributable to the owners of the parent company increased to CNY 2,853,258,955.46 from CNY 2,628,995,914.63, reflecting a growth of approximately 8.5%[37] - The company's short-term borrowings rose to CNY 919,000,000.00 from CNY 840,000,000.00, an increase of about 9.4%[35] Cash Flow - Net cash flow from operating activities increased by 39.87% to CNY 263,153,546.28[8] - Operating cash flow increased by 27.27% to ¥476,463,191.19, primarily due to rising revenues and reduced inventory[16] - The net cash flow from operating activities was CNY 476,463,191.19, an increase from CNY 374,368,403.61 in the previous year[56] - Financing activities generated a net cash inflow of CNY 257,160,478.96, a significant improvement from a net outflow of CNY -18,844,170.43 in the prior period[61] - Total cash and cash equivalents at the end of the period reached CNY 1,043,807,399.90, up from CNY 786,470,771.06 in the previous year, marking an increase of approximately 32.7%[60] Shareholder Information - The total number of shareholders at the end of the reporting period was 59,635[12] - The largest shareholder, Xinjiang Production and Construction Corps State-owned Assets Management Co., held 29.47% of shares[12] Government and Regulatory Matters - The company reported a government subsidy income of CNY 15,999,311.45 during the reporting period[9] - The company received a notice from the China Securities Regulatory Commission regarding the termination of the review of its non-public stock issuance application[19] Business Operations and Strategy - The company plans to raise up to ¥100 million through the issuance of convertible bonds for the construction of a pharmaceutical industrial park[17] - The company is focused on maintaining compliance with laws and regulations to avoid penalties or legal issues that could affect its operations[24] - The company is actively working on strategies to enhance its market position and operational efficiency through compliance and governance improvements[24] Commitments and Governance - The company reported a commitment to avoid competition with its subsidiaries, ensuring no similar business activities are conducted by the controlling shareholder[23] - The commitment includes ensuring that all related transactions are conducted fairly and transparently, minimizing any potential conflicts of interest[23] - The company has established measures to protect shareholder rights and ensure proper management of related party transactions[24] - The controlling shareholder has agreed to bear responsibility for any liabilities arising from past operational issues prior to the acquisition date[24] Performance Outlook - The net profit attributable to shareholders for 2017 is expected to range from 314.03 million to 431.80 million CNY, reflecting a decrease of 20% to an increase of 10% compared to 2016's net profit of 392.54 million CNY[28] - The decline in performance is attributed to lower product prices in the pig farming and plant protein businesses, while other business segments are expected to perform steadily[28] - The company commits to distributing at least 10% of the distributable profit as cash dividends annually over the next three years, contingent on meeting relevant legal and regulatory requirements[26] - The company plans to increase the cash dividend ratio or implement stock dividends if net profits continue to grow steadily over the next three years[26]

Financial Performance - Total assets at the end of the reporting period reached ¥4,715,024,529.94, an increase of 4.99% compared to the end of the previous year[8] - Net assets attributable to shareholders of the listed company amounted to ¥2,853,258,955.46, reflecting an 8.53% increase year-on-year[8] - Operating revenue for the reporting period was ¥1,196,626,639.72, representing a growth of 9.51% compared to the same period last year[8] - Net profit attributable to shareholders of the listed company was ¥130,849,143.58, up 3.08% year-on-year[8] - Basic earnings per share for the reporting period were ¥0.14, an increase of 7.69% compared to the same period last year[8] - The weighted average return on equity was 4.76%, a decrease of 0.40% compared to the previous year[8] - Net cash flow from operating activities reached ¥263,153,546.28, a significant increase of 39.87% compared to the previous year[8] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 59,635[12] - The largest shareholder, Xinjiang Production and Construction Corps State-owned Assets Management Company, held 29.47% of the shares[12] Asset Management - Accounts receivable increased by 269.50% to ¥582,464,350.65 due to changes in government procurement settlement methods in the pharmaceutical business[16] - Inventory decreased by 39.07% to ¥544,301,028.12 as previous period's inventory in the plant protein business was sold out[16] - Operating cash flow increased by 27.27% to ¥476,463,191.19 driven by revenue growth and reduced inventory[16] - Financial expenses rose by 41.85% to ¥17,915,922.73 primarily due to increased loans from business expansion[16] - The company reported a significant increase of 427.61% in business tax and additional fees to ¥11,217,788.63 due to changes in national tax policies[16] - Other receivables increased by 148.30% to ¥35,897,422.86 as a result of business scale expansion[16] Capital Raising and Regulatory Matters - The company plans to raise up to ¥100 million through convertible bonds for projects including the second phase of the pharmaceutical industrial park and pig farming industrialization[17] - The company received a notice from the China Securities Regulatory Commission regarding the termination of the review of its non-public stock issuance application[19] - The company is in the process of responding to feedback from the China Securities Regulatory Commission regarding its application for issuing convertible bonds[20] Commitments and Compliance - The company has commitments from shareholders and related parties to not transfer shares obtained through transactions for 36 months and 12 months, respectively, after listing[22] - The company reported that the controlling shareholder, Bingtuan State-owned Assets Company, will not engage in similar business activities as TianKang Bio and its subsidiaries[23] - The company has established commitments to avoid related party transactions and ensure compliance with legal regulations during shareholder meetings[23] - Bingtuan State-owned Assets Company has committed to maintaining the independence of the listed company according to the Company Law[23] - The company is currently fulfilling its commitments regarding share transfer restrictions and related party transactions[22] - The company has outlined measures to prevent any illegal occupation of its assets and funds by related parties[23] - The commitments made by Bingtuan State-owned Assets Company are effective and cannot be changed or revoked during its shareholding period[23] - The company will ensure that any unavoidable related party transactions are conducted at market rates and comply with legal procedures[23] - The company has established a compensation responsibility for any losses incurred due to non-fulfillment of commitments by related parties[23] - The company is actively working to maintain transparency and protect the rights of its shareholders[23] Restructuring and Mergers - The company is undergoing a significant asset restructuring involving the merger with Xinjiang Tiankang Holdings, which is expected to enhance operational efficiency and market presence[24] - The restructuring includes commitments from the involved parties to ensure compliance with legal and regulatory requirements, safeguarding the interests of the company and its shareholders[25] - The company has received assurances regarding the legality of operations and the absence of any significant liabilities or penalties from the past activities of Xinjiang Tiankang Holdings[26] - The commitments also cover potential liabilities arising from pre-merger activities, ensuring that any losses incurred will be compensated to the company[25] - The restructuring aims to consolidate assets and improve financial stability, with a focus on maintaining normal operations during the transition[26] - The company is ensuring that all necessary approvals and authorizations are in place for the merger, minimizing risks associated with the transaction[26] - The involved parties have guaranteed that there are no existing encumbrances or legal restrictions on the assets being transferred, facilitating a smooth merger process[26] - The company is committed to maintaining transparency and compliance throughout the restructuring process, with ongoing monitoring of legal and operational standards[25] - The merger is anticipated to create synergies that will enhance the company's competitive position in the market[24] - The company is focused on ensuring that all stakeholders are informed and protected during the restructuring, reinforcing its commitment to corporate governance[25] Future Projections and Dividends - The estimated net profit attributable to shareholders for 2017 is projected to be between ¥314.03 million and ¥431.80 million, representing a year-on-year change of -20% to 10%[29] - The net profit for 2016 attributable to shareholders was ¥392.54 million[29] - The decline in performance is attributed to decreased product prices in the pig farming and plant protein businesses, while other business segments remained stable[29] - The company commits to distributing cash dividends of no less than 10% of the distributable profit each year for the next three years, contingent on legal and regulatory compliance[28] - The company plans to increase the cash dividend ratio or implement stock dividends if net profits continue to grow steadily over the next three years[28] - The company will actively pursue cash profit distribution in accordance with relevant laws and regulations[28] Governance and Management - There are no violations regarding external guarantees during the reporting period[30] - There are no non-operating fund occupations by controlling shareholders or related parties during the reporting period[31] - The company has conducted institutional research and communication activities during the reporting period[33] - The chairman of the company is Yang Yan[34]

Financial Performance - The company's operating revenue for the first half of 2017 was CNY 2,269,473,254.95, representing a 4.88% increase compared to CNY 2,163,773,417.62 in the same period last year[23]. - The net profit attributable to shareholders of the listed company was CNY 189,752,358.05, a decrease of 1.14% from CNY 191,946,054.83 in the previous year[23]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 180,883,451.09, down 4.33% from CNY 189,073,522.39 year-on-year[23]. - The net cash flow from operating activities increased by 14.54% to CNY 213,309,644.91, compared to CNY 186,226,708.94 in the same period last year[23]. - Total assets at the end of the reporting period were CNY 4,685,603,190.98, up 4.34% from CNY 4,490,817,872.34 at the end of the previous year[23]. - The net assets attributable to shareholders of the listed company increased by 3.55% to CNY 2,722,409,811.88 from CNY 2,628,995,914.63 at the end of the previous year[23]. - The weighted average return on net assets decreased to 7.01% from 7.90% in the previous year[23]. - The company reported non-recurring gains of CNY 8,868,906.96 during the reporting period[28]. Revenue Breakdown - The sales revenue from the feed business was CNY 110,425.07 million, down 2.23% year-on-year, while the pharmaceutical business saw a revenue increase of 13.22% to CNY 26,597.74 million[37]. - The feed segment generated CNY 1,104,250,679.79 in revenue, accounting for 48.66% of total revenue, with a slight decrease of 2.23% compared to the previous year[47]. - The livestock farming segment saw a significant revenue increase of 57.67%, reaching CNY 102,017,492.66, with a gross margin of 49.94%[48]. - The veterinary medicine segment reported revenue of CNY 265,977,398.59, with a gross margin of 70.80%, reflecting a 13.22% increase in revenue year-on-year[48]. - Revenue from agricultural product processing increased by 30.28% to CNY 529,895,821.35, but the gross margin decreased to 3.95%[48]. - Revenue from the Xinjiang region accounted for 57.94% of total revenue, increasing by 18.87% year-on-year, while revenue from outside Xinjiang decreased by 9.74%[46]. Investment and R&D - The company invested CNY 19,328,131.53 in R&D, a decrease of 9.36% compared to the previous year[43]. - The total investment in the comprehensive feed project in Wujiaqu City reached 23,648.5 million yuan, with a cumulative actual investment of 36,660.3 million yuan, indicating a construction progress of 20.95%[58]. - The total investment in the comprehensive feed project in Yuanyang County was 27,761.4 million yuan, with a cumulative actual investment of 27,761.4 million yuan, reflecting a construction progress of 23.13%[58]. - The total actual investment across both projects amounted to 64,421.7 million yuan, with a planned investment of 51,410.0 million yuan[60]. Risks and Challenges - The company faces risks related to livestock disease outbreaks, raw material price fluctuations, and food safety issues that could impact its performance[6][7][9]. - The decline in the pig farming segment's performance is attributed to a decrease in domestic pig prices since May 2017, alongside a downturn in the plant protein business due to low cottonseed oil prices[73]. - The company faces risks from fluctuations in raw material prices, particularly corn and soybean meal, which could negatively impact feed business performance[75]. - To counteract raw material price volatility, the company has established storage companies in major production areas and is actively seeking new supply channels[75]. - The company has implemented measures to mitigate risks from animal diseases by enhancing disease prevention during pig farming and developing a complementary business model involving vaccines and feed[74]. Shareholder and Dividend Information - The company plans not to distribute cash dividends or issue bonus shares for the reporting period[10]. - The company has committed to distributing at least 10% of its distributable profits in cash annually over the next three years[88]. - The company plans to increase cash dividend ratios or implement stock dividends to enhance shareholder returns if net profits continue to grow steadily over the next three years[88]. - The company did not distribute cash dividends or issue bonus shares for the first half of the year[82]. Subsidiary Performance - The subsidiary Xinjiang Kuitun Tiankang Plant Protein Co., Ltd. reported a net loss of 5,854,127.3 yuan on total revenue of 237,889,016 yuan[71]. - The subsidiary Xinjiang Akesu Tiankang Plant Protein Co., Ltd. reported a net loss of 5,587,310.8 yuan on total revenue of 337,990,035 yuan[71]. - The subsidiary Henan Hongzhan Industry Co., Ltd. reported a net loss of 234,117.38 yuan on total revenue of 343,858,040 yuan[71]. - The subsidiary Shenyang Tiankang Feed Co., Ltd. reported a net loss of 2,156,130.2 yuan on total revenue of 13,716,986.4 yuan[71]. Corporate Governance and Compliance - The company has committed to maintaining transparency and accuracy in the information provided regarding its assets and liabilities[88]. - The company has established a commitment to reduce and regulate related party transactions[85]. - The company has ensured that any related party transactions will follow market principles and legal procedures[85]. - The company has confirmed that all commitments made during the asset restructuring have been fulfilled[84]. - The company has undertaken to avoid any illegal occupation of funds and assets of the company and its subsidiaries[85]. - The company has committed to fulfilling its obligations under relevant laws and regulations to protect the rights of its shareholders[85]. Financial Position and Assets - Cash and cash equivalents at the end of the reporting period were CNY 1,055,301,189.00, representing 22.52% of total assets, an increase from 13.24% at the end of the previous year[50]. - Short-term borrowings increased significantly to CNY 1,064,000,000.00, accounting for 22.71% of total liabilities, due to increased bank loans[51]. - The company reported a decrease in inventory turnover, with inventory valued at CNY 777,753,778.60, representing 16.60% of total assets[50]. - The total amount of guarantees approved during the reporting period was CNY 105 million, with actual guarantees amounting to CNY 79 million[105]. - The total amount of guarantees at the end of the reporting period was CNY 87 million, with actual guarantees amounting to CNY 65.5 million[105]. - The proportion of actual guarantee total to the company's net assets was 24.06%[105]. Market Expansion and Strategy - The company is actively pursuing market expansion and new product development strategies to enhance its competitive position in the industry[56]. - The company plans to gradually expand its "company + farmer" breeding model as its pig farming scale increases[39]. - The company has plans for market expansion and new product development in the feed and veterinary sectors, aiming to enhance its competitive edge[173]. Accounting and Financial Reporting - The company's financial statements are prepared based on actual transactions and events, adhering to accounting standards[175]. - The company adheres to the Accounting Standards for Business Enterprises, ensuring that financial statements accurately reflect its financial position, operating results, and cash flows for the reporting period[181]. - The accounting period for the company runs from January 1 to December 31 each year[178]. - The company uses the Chinese Yuan (RMB) as its functional currency for accounting purposes[180].

Revenue and Profitability - Revenue for Q1 2017 was CNY 1,039,393,448.53, an increase of 8.00% compared to CNY 962,437,096.19 in the same period last year[8] - Net profit attributable to shareholders was CNY 107,299,493.78, reflecting an 11.12% increase from CNY 96,557,711.33 year-on-year[8] - Basic earnings per share increased by 10.00% to CNY 0.11 from CNY 0.10 in the same period last year[8] - The expected net profit attributable to shareholders for the first half of 2017 is projected to range from 172.75 million to 230.34 million yuan, reflecting a change of -10.00% to 20.00% compared to the same period in 2016[24] - The net profit for the first half of 2016 was 191.95 million yuan, indicating a potential decline in profitability due to reduced feed business performance[24] Cash Flow - Net cash flow from operating activities was negative CNY 14,031,872.75, a decline of 107.66% compared to CNY 183,192,982.36 in the previous year[8] - The net cash flow from operating activities decreased by 107.66% compared to the same period last year, primarily due to increased costs and higher cash payments for raw material procurement[19] - The net cash flow from investing activities increased by 59.9% year-on-year, mainly because there were no subsidiary acquisitions in the current period[19] - The net cash flow from financing activities decreased by 1.48% compared to the same period last year, attributed to a slight decline in net loans and repayments[19] Assets and Shareholder Equity - Total assets at the end of the reporting period were CNY 4,453,599,016.06, a decrease of 0.83% from CNY 4,490,817,872.34 at the end of the previous year[8] - Net assets attributable to shareholders increased by 4.08% to CNY 2,736,295,408.41 from CNY 2,628,995,914.63 at the end of the previous year[8] Receivables - Accounts receivable increased by 94.66% compared to the beginning of the year, primarily due to planned government procurement arrears from the pharmaceutical business[17] - Other receivables rose by 122.03% compared to the beginning of the year, mainly due to an increase in travel advance funds[18] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 65,904[12] Non-Operating Income - The company reported non-operating income of CNY 5,734,263.29, which includes government subsidies and other income[9]

Financial Performance - The company's operating revenue for 2016 was approximately ¥4.44 billion, representing a 6.64% increase compared to ¥4.17 billion in 2015[21]. - The net profit attributable to shareholders for 2016 was approximately ¥392.54 million, a significant increase of 59.70% from ¥245.79 million in 2015[21]. - The net profit after deducting non-recurring gains and losses was approximately ¥355.50 million, reflecting a 111.84% increase from ¥167.82 million in 2015[21]. - The basic earnings per share for 2016 was ¥0.41, up 51.85% from ¥0.27 in 2015[21]. - The total assets at the end of 2016 were approximately ¥4.49 billion, an 18.02% increase from ¥3.81 billion at the end of 2015[22]. - The net assets attributable to shareholders at the end of 2016 were approximately ¥2.63 billion, an increase of 11.78% from ¥2.35 billion at the end of 2015[22]. - The net cash flow from operating activities for 2016 was approximately ¥316.05 million, a decrease of 38.29% from ¥512.19 million in 2015[21]. - The weighted average return on net assets for 2016 was 15.82%, an increase of 4.92% from 10.90% in 2015[22]. Revenue Breakdown - The sales revenue from the feed business was 2,220.31 million yuan, a decrease of 6.51% year-on-year, accounting for 49.96% of total revenue[38]. - The sales volume of animal vaccines decreased by 17.93%, with a total of 126.66 million doses sold[38]. - In 2016, the company's sales revenue from pig farming and food processing was CNY 711.37 million, a year-on-year increase of 38.75%, accounting for 16.01% of total revenue[39]. - The sales revenue from plant protein and oil processing reached CNY 626.79 million, up 43.80% year-on-year, contributing 14.10% to total revenue[39]. - The pharmaceutical segment's revenue was CNY 751.74 million, a decrease of 2.87% year-on-year, with a gross margin of 57.56%[46]. Dividend Distribution - The company plans to distribute a cash dividend of ¥1.00 per 10 shares, based on a total of 963,384,608 shares[8]. - In 2016, the company distributed a total cash dividend of 96,338,460.80 CNY, which is 100% of the distributable profit[113]. - The cash dividend per 10 shares for 2016 was set at 1.00 CNY (including tax)[112]. - The retained earnings after the 2016 dividend distribution amounted to 602,189,273.35 CNY, which will be used to supplement the company's working capital[113]. - The company aims to maintain a minimum cash dividend ratio of 20% during profit distributions, considering its growth stage and significant capital expenditure plans[113]. Research and Development - The company reported a significant increase in R&D investment, enhancing its technological innovation capabilities[35]. - Research and development personnel increased to 115 in 2016, a rise of 4.55% from 110 in 2015, with R&D investment amounting to ¥77,528,908.31, up 28.32% from ¥60,418,239.14 in 2015[70]. - The proportion of R&D investment to operating revenue rose to 1.74% in 2016 from 1.45% in 2015, reflecting a strategic focus on innovation[70]. - The company is accelerating the research and development of new animal vaccines to create new growth points for its pharmaceutical business[98]. Market Expansion and Strategy - The company plans to expand its market presence through acquisitions and technological upgrades in the food and pharmaceutical sectors[33]. - The company is preparing for the export of the new vaccine due to restrictions on live vaccines, indicating a strategic market expansion initiative[69]. - The company aims to expand its international business by establishing an export team and achieving breakthroughs in key vaccine products[98]. - The company is focusing on the accelerated development of large-scale pig farming, with a shift in production areas expected during the 14th Five-Year Plan[88]. Risk Management - The company faces risks related to livestock disease, raw material price fluctuations, and food safety, which could impact future performance[4][5][8]. - The company will strengthen disease prevention and management practices to mitigate risks from livestock epidemics, raw material price fluctuations, and food safety[101][102][104]. Corporate Governance and Compliance - The company has established a comprehensive governance structure in accordance with relevant laws and regulations, ensuring clear responsibilities and mutual checks among the board, management, and shareholders[153]. - The company is committed to transparency and compliance in all related party transactions, adhering to market principles[115]. - The company has fulfilled all commitments made by its actual controllers and shareholders during the reporting period[114]. - The company has not engaged in any major litigation or arbitration during the reporting period[126]. Employee Management - The total number of employees in the company is 2,393, with 632 in the parent company and 1,761 in major subsidiaries[194]. - The company emphasizes a performance-oriented culture to enhance employee efficiency and effectiveness, aiming to improve management levels and operational performance[196]. - A four-tier training system has been established to meet the training needs of employees at different levels, with 100 participants trained in standardized breeding technology[197]. Financial Management - The company has maintained a stable financial status with no significant accounting errors or changes in accounting policies during the reporting period[120][121]. - The company has engaged Sigma Accounting Firm for auditing services, with a fee of 1.2 million yuan for the reporting period[123]. - The company has not reported any major guarantees involving related parties during the reporting period[134]. Shareholder Information - The largest shareholder, Xinjiang Production and Construction Corps, holds 29.47% of the shares, totaling 283,929,192 shares[166]. - The total number of shareholders at the end of the reporting period was 63,105[166]. - The company has a significant number of shares held by institutional investors, including 159,153,329 shares held by China New Capital Investment Co., Ltd.[167].

Financial Performance - Net profit attributable to shareholders rose by 79.07% to CNY 126,938,759.87 for the current period[9] - Operating revenue for the current period was CNY 1,092,700,842.11, reflecting a 0.69% increase year-on-year[9] - Basic earnings per share increased by 85.71% to CNY 0.13[9] - The weighted average return on net assets improved to 5.16%, up from 1.98% in the previous year[9] - The net cash flow from operating activities for the year-to-date was CNY 374,368,403.61, a 45.62% increase[9] - Operating profit for the current period was ¥141,124,519.61, significantly higher than ¥66,095,085.10 in the previous period, indicating an increase of approximately 113%[41] - Net profit attributable to shareholders of the parent company was ¥126,938,759.87, compared to ¥70,889,139.98 in the previous period, reflecting an increase of around 79%[41] - Net profit for the period was CNY 317,221,749.63, compared to CNY 210,366,889.77 in the same period last year, reflecting a significant increase of about 50.8%[49] - Earnings per share (EPS) for the current period was CNY 0.33, up from CNY 0.22 in the previous period, indicating a growth of 50%[50] Assets and Liabilities - Total assets increased by 7.28% to CNY 4,082,141,296.49 compared to the end of the previous year[9] - Current assets totaled ¥2,197,507,614.72, up from ¥2,065,782,845.79 at the start of the year[32] - The company's total liabilities as of September 30, 2016, were ¥1,453,861,567.51, compared to ¥1,420,041,774.94 at the beginning of the year[34] - The company's retained earnings increased significantly to ¥900,943,255.68 from ¥697,664,593.94, reflecting strong profit retention[35] - The company's total liabilities increased to ¥1,040,579,946.91 from ¥851,803,206.90, indicating a rise of about 22.2%[38] Cash Flow - Cash inflow from operating activities totaled CNY 2,761,357,778.08, a decrease of 5.4% from CNY 2,919,952,628.16 in the previous period[56] - Net cash flow from operating activities increased to CNY 374,368,403.61, up 45.7% from CNY 257,084,981.91 in the previous period[57] - Cash outflow for purchasing goods and services was CNY 1,910,820,821.43, down 6.5% from CNY 2,043,374,007.06[56] - Cash flow from investing activities resulted in a net outflow of CNY 253,756,547.43, compared to a smaller outflow of CNY 48,494,713.65 in the previous period[57] - Cash inflow from financing activities was CNY 527,000,000.00, down 30.4% from CNY 757,050,000.00 in the previous period[57] Shareholder Information - The total number of shareholders at the end of the reporting period was 63,891[13] - The largest shareholder, Xinjiang Production and Construction Corps, holds 29.47% of the shares[13] Government and Regulatory Compliance - The company reported a government subsidy of CNY 5,740,989.26 during the period[10] - The company is in compliance with all applicable laws and regulations, ensuring no penalties or legal issues arise from its operations[23] - The company has committed to maintaining its independence in operations, assets, and finances, adhering to relevant laws and regulations[22] Inventory and Receivables - Accounts receivable increased by 307.37% to ¥570,264,179.69 due to government procurement sales and quarterly credit sales in the feed business[17] - Inventory decreased by 38.99% to ¥470,761,185.26 as a result of completed sales in the oil business and reduced raw materials in the feed business[17] - Other receivables increased by 56.19% to ¥81,104,365.52 due to increased personnel expense reserves from business expansion[17] Future Plans and Commitments - The company plans to actively distribute profits through cash dividends over the next three years, in accordance with legal and regulatory requirements[23] - The company plans to distribute cash dividends of no less than 10% of the distributable profit achieved in the current year, with potential increases in the dividend ratio if net profits continue to grow steadily over the next three years[24]